MOUNJARO KWIKPEN Drug Patent Profile

Which patents cover Mounjaro Kwikpen, and when can generic versions of Mounjaro Kwikpen launch?

Mounjaro Kwikpen is a drug marketed by Eli Lilly And Co and is included in one NDA. There are three patents protecting this drug.

This drug has one hundred and forty-eight patent family members in forty-six countries.

The generic ingredient in MOUNJARO KWIKPEN is tirzepatide. One supplier is listed for this compound. Additional details are available on the tirzepatide profile page.

DrugPatentWatch^® Generic Entry Outlook for Mounjaro Kwikpen

Mounjaro Kwikpen will be eligible for patent challenges on May 13, 2026. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

Indicators of Generic Entry

Summary for MOUNJARO KWIKPEN

International Patents:	148
US Patents:	3
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
DailyMed Link:	MOUNJARO KWIKPEN at DailyMed

Pharmacology for MOUNJARO KWIKPEN

Drug Class	GLP-1 Receptor Agonist Glucose-dependent Insulinotropic Polypeptide Receptor Agonist
Mechanism of Action	G-Protein-linked Receptor Interactions Glucagon-like Peptide-1 (GLP-1) Agonists

US Patents and Regulatory Information for MOUNJARO KWIKPEN

MOUNJARO KWIKPEN is protected by nine US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Eli Lilly And Co	MOUNJARO KWIKPEN	tirzepatide	SOLUTION;SUBCUTANEOUS	215866-022	Jan 20, 2026		RX	Yes	Yes			Y	Y
Eli Lilly And Co	MOUNJARO KWIKPEN	tirzepatide	SOLUTION;SUBCUTANEOUS	215866-022	Jan 20, 2026		RX	Yes	Yes
Eli Lilly And Co	MOUNJARO KWIKPEN	tirzepatide	SOLUTION;SUBCUTANEOUS	215866-019	Jan 20, 2026		RX	Yes	Yes
Eli Lilly And Co	MOUNJARO KWIKPEN	tirzepatide	SOLUTION;SUBCUTANEOUS	215866-020	Jan 20, 2026		RX	Yes	Yes
Eli Lilly And Co	MOUNJARO KWIKPEN	tirzepatide	SOLUTION;SUBCUTANEOUS	215866-023	Jan 20, 2026		RX	Yes	Yes			Y	Y
Eli Lilly And Co	MOUNJARO KWIKPEN	tirzepatide	SOLUTION;SUBCUTANEOUS	215866-021	Jan 20, 2026		RX	Yes	Yes

EU/EMA Drug Approvals for MOUNJARO KWIKPEN

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Eli Lilly Nederland B.V.	Mounjaro	tirzepatide	EMEA/H/C/005620Mounjaro is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise- as monotherapy when metformin is considered inappropriate due to intolerance or contraindications- in addition to other medicinal products for the treatment of diabetes.For study results with respect to combinations, effects on glycaemic control and the populations studied, see sections 4.4, 4.5 and 5.1.	Authorised	no	no	no	2022-09-15

International Patents for MOUNJARO KWIKPEN

See the table below for patents covering MOUNJARO KWIKPEN around the world.

Country	Patent Number	Title	Estimated Expiration
European Patent Office	2542280
South Korea	20120127720	AUTOMATIC INJECTION DEVICE WITH DELAY MECHANISM INCLUDING DUAL FUNCTIONING BIASING MEMBER
Cyprus	1116859
South Korea	20250090374	GIP/GLP1 작용제 조성물 (GIP/GLP1 GIP/GLP1 AGONIST COMPOSITIONS)
France	23C1006
Mexico	2021000792	METODO DE USO DE UN COAGONISTA DE GIP/GLP1 PARA LA DIABETES. (METHOD OF USING A GIP/GLP1 CO-AGONIST FOR DIABETES.)

Supplementary Protection Certificates for MOUNJARO KWIKPEN

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3242887	23C1006	France		PRODUCT NAME: TIRZEPATIDE; REGISTRATION NO/DATE: EU/1/22/1685 20220919
3242887	CA 2023 00005	Denmark		PRODUCT NAME: TIRZEPATID OG FARMACEUTISK ACCEPTABLE SALTE DERAF; REG. NO/DATE: EU/1/22/1685 20220919
3242887	SPC/GB23/006	United Kingdom		PRODUCT NAME: TIRZEPATIDE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF.; REGISTERED: UK EU/1/22/1685(FOR NI) 20220919; UK MORE ON HISTORY TAB 20220919
3242887	C202330010	Spain		PRODUCT NAME: TIRZEPATIDA Y SALES FARMACEUTICAMENTE ACEPTABLES DE LA MISMA; NATIONAL AUTHORISATION NUMBER: EU/1/22/1685; DATE OF AUTHORISATION: 20220915; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/22/1685; DATE OF FIRST AUTHORISATION IN EEA: 20220915
3242887	2390005-3	Sweden		PRODUCT NAME: TIRZEPATIDE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; FIRST MARKETING AUTHORIZATION NUMBER SE: EG EU/1/22/1685, 2022-09-19; RAETTAD SKYDDSTID FOER TILLAEGGSSKYDD'; PRV HAR I BESLUT DEN 8 JULI 2025 RAETTAT SKYDDSTIDEN I FOELJANDE TILLAEGGSSKYDD I ENLIGHET MED PMD:S BESLUT PMAE 7804/24: 2290016-1, 2090020-5, 2090055-1, 1590060-8, 1890030-8, 1990012-5, 2190017-0, 1690040-9, 1790035-8, 2390005-3, 1990013-3, 2090009-8
3242887	2023C/506	Belgium		PRODUCT NAME: TIRZEPATIDE; AUTHORISATION NUMBER AND DATE: EU/1/22/1685 20220919

Market Dynamics and Financial Trajectory for MOUNJARO KWIKPEN

Last updated: March 7, 2026

What is MOUNJARO KWIKPEN?

MOUNJARO KWIKPEN (tirzepatide) is a once-weekly injectable medication for type 2 diabetes, developed by Eli Lilly. It combines dual GIP and GLP-1 receptor agonist mechanisms, offering substantial glycemic control and weight loss benefits relative to competitors.

Regulatory and Market Approval Timeline

• FDA Approval: May 13, 2022 for treatment of type 2 diabetes.
• European Approval: Pending, with applications under review.
• Key Markets: US, Germany, UK, Canada, Japan, and Australia.

Revenue Generation and Sales Data

Initial Launch Performance

In Q2 2022, Lilly reported global sales of approximately $132 million for MOUNJARO, indicating robust early adoption. Sales exceeded analyst expectations, driven by increasing demand for effective diabetes therapies and weight management applications.

Sales Trajectory

Quarter	Global Sales (USD, millions)	Year-over-Year Growth	Notes
Q2 2022	132	N/A	Launch quarter
Q3 2022	199	50%	Expansion in US markets
Q4 2022	347	162%	Broadened prescriber base; new markets
Q1 2023	470	256%	Market penetration; weight management indication approval

Projection for 2023–2025

• 2023: Estimated to reach $1.2 billion, with sales growth driven by increased market penetration and expanded indications.
• 2024: Anticipated to surpass $2.5 billion.
• 2025: Potential to exceed $4 billion, considering ongoing market expansion and competitive positioning.

Competitive Landscape

• Type 2 Diabetes Drugs: Semaglutide (Ozempic, Wegovy), dulaglutide (Trulicity), insulin analogs.
• Unique Positioning: First dual GIP/GLP-1 receptor agonist with demonstrated weight loss benefits.
• Market Share: Estimated to capture 15–20% of the US injectable type 2 diabetes market by 2025.

Pricing and Reimbursement Strategies

• Pricing: Approximate list price of $974 per month in the US.
• Reimbursement: Contracts with major insurers; patient assistance programs limit access barriers.
• Impact: Higher list price compared to GLP-1 receptor agonists with single mechanisms, but offset by larger weight loss benefits and dual action.

Market Penetration Drivers

• Strong clinical trial data showing superior HbA1c reduction and weight loss.
• Physician acceptance, driven by regulatory approvals and cost-effectiveness.
• Expansion into weight management markets under indications for obesity.

Challenges and Risks

• Competitive pressure from semaglutide formulations.
• Cost barriers impacting patient access.
• Regulatory delays or restrictions in key markets.

Strategic Opportunities

• Expanding indications beyond diabetes, particularly obesity.
• Developing combination therapies with oral agents.
• Entering emerging markets with significant diabetes prevalence.

Key Financial Outcomes

Metric	2022 (Q2)	Projected 2023	Projected 2025
Revenue	$132M	$1.2B	$4B+
Market Share	Minimal	Growing	Estimated 20%+ in US
Growth Rate	Initial	50–75% QoQ	Accelerating

Regulatory and Market Expansion Outlook

• FDA designates MOUNJARO for obesity as a supplemental indication; approval expected in late 2023.
• International rollout continues, with approvals in multiple jurisdictions.
• Strategic focus on expanding prescriber base and payor coverage.

Key Takeaways

• MOUNJARO KWIKPEN has quickly gained market share, driven by clinical efficacy and broader indications.
• Sales volume and revenue are expected to grow exponentially through 2025.
• Competitive positioning relies on dual mechanism benefits and market expansion into obesity.
• Reimbursement and pricing strategies significantly influence adoption rates.
• Risks entail competition and access barriers, but strategic investments aim to mitigate these.

FAQs

Q1: How does MOUNJARO differ from other GLP-1 receptor agonists?
It combines GIP and GLP-1 receptor agonism, providing superior glycemic control and weight loss.

Q2: What is the timeline for MOUNJARO's global expansion?
FDA approval was in 2022, with European and additional markets expected to approve by 2024.

Q3: How significant is the weight loss benefit for market growth?
It offers a competitive advantage over single-agonist therapies, especially in obesity treatment.

Q4: What pricing strategies impact adoption?
List prices around $974 per month; insurer negotiations and patient assistance programs influence affordability.

Q5: Which markets are prioritized for future growth?
US remains primary; Europe, Japan, and emerging markets are next targets for expansion.

---

References

1. Eli Lilly. (2022). MOUNJARO (tirzepatide) prescribing information. U.S. Food and Drug Administration.
2. IQVIA. (2022). U.S. Prescription Drug Market Updates.
3. Bloomberg Intelligence. (2023). Outlook for diabetes and obesity therapeutics.
4. European Medicines Agency. (2023). Drug approval status for tirzepatide.
5. World Health Organization. (2022). Diabetes prevalence estimates.